Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity
Open Access
- 1 November 2005
- journal article
- Published by American Society of Hematology in Blood
- Vol. 106 (9) , 3058-3061
- https://doi.org/10.1182/blood-2005-04-1422
Abstract
Low-dose metronomic chemotherapy is a promising therapeutic cancer treatment strategy thought to have an antiangiogenic basis. However, the advantageKeywords
This publication has 23 references indexed in Scilit:
- The splenic microenvironment is a source of proangiogenesis/inflammatory mediators accelerating the expansion of murine erythroleukemic cellsBlood, 2005
- A Multitargeted, Metronomic, and Maximum-Tolerated Dose “Chemo-Switch” Regimen is Antiangiogenic, Producing Objective Responses and Survival Benefit in a Mouse Model of CancerJournal of Clinical Oncology, 2005
- Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: Implications for cellular surrogate marker analysis of antiangiogenesisCancer Cell, 2005
- A Comparative Analysis of Low-Dose Metronomic Cyclophosphamide Reveals Absent or Low-Grade Toxicity on Tissues Highly Sensitive to the Toxic Effects of Maximum Tolerated Dose RegimensCancer Research, 2004
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinomaCancer, 2003
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002
- Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levelsAnnals of Oncology, 2002
- Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in miceJournal of Clinical Investigation, 2000
- Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicityJournal of Clinical Investigation, 2000